News
ADPT
29.48
-1.54%
-0.46
Adaptive Biotechnologies (ADPT) Lands In $17.1 Billion DNA Sequencing Market Report
Simply Wall St · 20h ago
Adaptive Biotechnologies price target raised to $35 from $27 at Piper Sandler
TipRanks · 2d ago
Adaptive Biotechnologies Is Maintained at Buy by Guggenheim
Dow Jones · 2d ago
Adaptive Biotechnologies Price Target Raised to $34.00/Share From $32.00 by Guggenheim
Dow Jones · 2d ago
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Zura Bio (ZURA), Adaptive Biotechnologies (ADPT) and Editas Medicine (EDIT)
TipRanks · 2d ago
Adaptive Biotechnologies (ADPT) Stock Looks Reasonable As Cash Flow Recovery Takes Shape
Simply Wall St · 2d ago
Adaptive Biotechnologies price target raised to $35 from $30 at JPMorgan
TipRanks · 3d ago
Is Adaptive Biotechnologies (ADPT) Still Below Fair Value On Mixed Q3 Results?
Simply Wall St · 4d ago
Weekly Report: what happened at ADPT last week (1102-1106)?
Weekly Report · 4d ago
Adaptive (ADPT) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/05 15:13
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Adaptive Biotechnologies (ADPT)
TipRanks · 11/05 14:10
Piper Sandler Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
TipRanks · 11/05 12:29
At a glance: stocks gapping up premarket
Seeking Alpha · 11/05 12:25
Quarterly Sales Slip Might Change The Case For Investing In Adaptive Biotechnologies (ADPT)
Simply Wall St · 11/05 11:43
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 11/04 23:00
Adaptive Biotechnologies Q3 2026 Earnings Call Transcript
Benzinga · 11/04 22:36
Adaptive Biotechnologies raises FY26 revenue view to $276M-$286M
TipRanks · 11/04 22:30
Adaptive Biotechnologies reports Q3 EPS 2c, consensus (10c)
TipRanks · 11/04 22:25
Adaptive Biotechnologies GAAP EPS of $0.02 beats by $0.11, revenue of $83.9M beats by $12.3M
Seeking Alpha · 11/04 21:20
More
Webull provides a variety of real-time ADPT stock news. You can receive the latest news about Adaptive Biotechnologies through multiple platforms. This information may help you make smarter investment decisions.
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.